On August 21, Tempus AI rose 5.82% in regular trading, trading at $70.33 per share, with turnover of $317 million, extending its recent strong performance.

On the news front, Moderna and Merck previously disclosed that their personalized mRNA cancer vaccine combined with Keytruda met the primary endpoint in a Phase 3 interim analysis for melanoma, marking the first personalized mRNA cancer vaccine to demonstrate efficacy in a late-stage trial globally. The vaccine requires customization based on each patient's tumor DNA, directly benefiting the tumor gene sequencing supply chain.

Tempus AI is currently acquiring Personalis for $1.5 billion to integrate molecular residual disease detection into its AI-driven precision oncology platform. This acquisition positions Tempus AI in close alignment with the personalized vaccine supply chain, as its platform connects laboratory results with patient clinical data for individualized testing. The stock has gained approximately 36% over the past three trading sessions amid these catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)